MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-021-01499-z

Медицинская библиотека · Nature medicine · 2021

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

Kyriazopoulou Evdoxia, Poulakou Garyfallia, Milionis Haralampos, Metallidis Simeon, Adamis Georgios, Tsiakos Konstantinos, Fragkou Archontoula, Rapti Aggeliki, Damoulari Christina, Fantoni Massimo, Kalomenidis Ioannis, Chrysos Georgios, Angheben Andrea, Kainis Ilias, Alexiou Zoi, Castelli Francesco, Serino Francesco Saverio, Tsilika Maria, Bakakos Petros, Nicastri Emanuele, Tzavara Vassiliki, Kostis Evangelos, Dagna Lorenzo, Koufargyris Panagiotis, Dimakou Katerina, Savvanis Spyridon, Tzatzagou Glykeria, Chini Maria, Cavalli Giulio, Bassetti Matteo, Katrini Konstantina, Kotsis Vasileios, Tsoukalas George, Selmi Carlo, Bliziotis Ioannis, Samarkos Michael, Doumas Michael, Ktena Sofia, Masgala Aikaterini, Papanikolaou Ilias, Kosmidou Maria, Myrodia Dimitra-Melia, Argyraki Aikaterini, Cardellino Chiara Simona, Koliakou Katerina, Katsigianni Eleni-Ioanna, Rapti Vassiliki, Giannitsioti Efthymia, Cingolani Antonella, Micha Styliani, Akinosoglou Karolina, Liatsis-Douvitsas Orestis, Symbardi Styliani, Gatselis Nikolaos, Mouktaroudi Maria, Ippolito Giuseppe, Florou Eleni, Kotsaki Antigone, Netea Mihai G, Eugen-Olsen Jesper, Kyprianou Miltiades, Panagopoulos Periklis, Dalekos George N, Giamarellos-Bourboulis Evangelos J

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml-1, 85.9% (n = 510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95% confidence interval 0.26-0.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40, P < 0.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter.

Для цитирования: Kyriazopoulou Evdoxia, Poulakou Garyfallia, Milionis Haralampos, Metallidis Simeon, Adamis Georgios, Tsiakos Konstantinos, Fragkou Archontoula, Rapti Aggeliki, Damoulari Christina, Fantoni Massimo, Kalomenidis Ioannis, Chrysos Georgios, Angheben Andrea, Kainis Ilias, Alexiou Zoi, Castelli Francesco, Serino Francesco Saverio, Tsilika Maria, Bakakos Petros, Nicastri Emanuele, Tzavara Vassiliki, Kostis Evangelos, Dagna Lorenzo, Koufargyris Panagiotis, Dimakou Katerina, Savvanis Spyridon, Tzatzagou Glykeria, Chini Maria, Cavalli Giulio, Bassetti Matteo, Katrini Konstantina, Kotsis Vasileios, Tsoukalas George, Selmi Carlo, Bliziotis Ioannis, Samarkos Michael, Doumas Michael, Ktena Sofia, Masgala Aikaterini, Papanikolaou Ilias, Kosmidou Maria, Myrodia Dimitra-Melia, Argyraki Aikaterini, Cardellino Chiara Simona, Koliakou Katerina, Katsigianni Eleni-Ioanna, Rapti Vassiliki, Giannitsioti Efthymia, Cingolani Antonella, Micha Styliani, Akinosoglou Karolina, Liatsis-Douvitsas Orestis, Symbardi Styliani, Gatselis Nikolaos, Mouktaroudi Maria, Ippolito Giuseppe, Florou Eleni, Kotsaki Antigone, Netea Mihai G, Eugen-Olsen Jesper, Kyprianou Miltiades, Panagopoulos Periklis, Dalekos George N, Giamarellos-Bourboulis Evangelos J. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.. Nature medicine. 2021. DOI: 10.1038/s41591-021-01499-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.